Mitral-Valve Prolapse Less Common, Less Harmful Than Previously Thought
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Mitral-Valve Prolapse Less Common, Less Harmful Than Previously Thought

WASHINGTON, DC -- July 2, 1999 -- Researchers from the National Heart, Lung and Blood Institute's (NHLBI) Framingham Heart Study report that mitral-valve prolapse (MVP), a condition in which a valve in the heart is abnormally long and floppy, is substantially less common and less serious than previously believed.

In a study appearing in yesterday’s issue of The New England Journal of Medicine, the researchers report that MVP affects about two percent of the population rather than the five to 35 percent of the population indicated in earlier estimates. And, contradicting earlier studies suggesting that MVP occurs more commonly in women, the researchers found that men and women are equally likely to have the condition.

"This is very compelling information," said Dr. Claude Lenfant, director of the NHLBI, "It may mean people who have been diagnosed with mitral valve prolapse should consult their physician to discuss their health status. It also indicates that further, longer-term studies are called for to resolve this issue definitively and to define the natural history of this condition."

Diagnoses of mitral-valve prolapse increased significantly in the late 1970s and early 1980s with the advent of ultrasound technology which, for the first time, enabled doctors to view the mitral valve noninvasively. Dr. Emelia Benjamin, the senior investigator, said the earlier studies were conducted using M-mode technology, a form of echocardiography, and often resulted in over diagnosis of MVP. This study was undertaken in part because of the availability of newer, more accurate echocardiographic criteria for mitral-valve prolapse developed by co-author Robert Levine, MD. The criteria allowed the researchers to address the validity of the diagnosis of mitral-valve prolapse occurring in an alarming proportion of the population.

Using standard echocardiographic equipment along with the new criteria, which minimises false positive and false negative diagnoses, the researchers evaluated mitral-valve prolapse status in 3,491 participants in the Framingham Heart Study. Of these, 84 (2.4 percent) had MVP.

"With this study, we may have tempered the notion that mitral-valve prolapse is the most common cardiac valvular abnormality in industrialised countries," said Dr. Lisa Freed, the study's lead author. "In addition, the low frequency of associated complications may allay anxiety for those in whom mitral-valve prolapse is diagnosed in an outpatient setting."

Dr. Benjamin noted the value of conducting this study in a community setting because community studies give a more representative picture of MVP and its clinical features.

"Prior studies using echocardiography have involved patients in university hospitals who tend to have more severe abnormalities or symptoms," she said.

In addition to being thought to have a high prevalence rate, MVP has often been portrayed as a disease with frequent and serious complications, including stroke, atrial fibrillation and heart failure. The researchers found that these complications did not occur at higher rates among patients with mitral-valve prolapse compared to those patients without prolapse.

The authors point out that the participants in this study were predominantly white and the results may not apply to other ethnic and racial groups.

Another NHLBI-funded study on MVP appearing in the same issue of The New England Journal of Medicine found that the condition was no more common among young people (45 years old or younger) with stroke or transient ischemic stroke (TIA or mini stroke) than it was among a control group of patients. The issue of a possible connection between MVP and stroke -- especially in young patients -- has been a long-standing controversy.

The new study by Dan Gilon, M.D., Robert Levine, M.D. (a co-author of the Framingham study), and colleagues at Massachusetts General Hospital and Harvard Medical School also involved the use of the same new, more accurate echocardiographic criteria. The scientists report that they could not show an association between MVP and acute ischemic neurologic events (stroke) in young people.

Related Links: The New England Journal of Medicine.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities